OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

By: via Benzinga
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Borealis-2™, an investigator-sponsored, randomized Phase 2 trial, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.